CoChat

Limitations of Contemporary Guidelines for Managing Patients at High Genetic Risk of Coronary Artery Disease

Open access
Aragam, Krishna G., Dobbyn, Amanda, Judy, Renae, Chaffin, Mark, Chaudhary, Kumardeep, Hindy, George, Cagan, Andrew, Finneran, Phoebe, Weng, Lu-Chen, Loos, Ruth J.F., Nadkarni, Girish, Cho, Judy H., Kember, Rachel L., Baras, Aris, Reid, Jeffrey, Overton, John, Philippakis, Anthony, Ellinor, Patrick T., Weiss, Scott T., Rader, Daniel J., Lubitz, Steven A., Smoller, Jordan W., Karlson, Elizabeth W., Khera, Amit V., Kathiresan, Sekar, Do, Ron, Damrauer, Scott M., Natarajan, Pradeep · 2020 · Journal of the American College of Cardiology
Cited by 138

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

Background: Polygenic risk scores (PRS) for coronary artery disease (CAD) identify high-risk individuals more likely to benefit from primary prevention statin therapy. Whether polygenic CAD risk is captured by conventional paradigms for assessing clinical cardiovascular risk remains unclear. Objectives: To intersect polygenic risk with guideline-based recommendations and management patterns for CAD primary prevention. Methods: We applied a genome-wide CAD PRS to 47,108 individuals across three U.S. healthcare systems. We then assessed whether primary prevention patients at high polygenic risk might be distinguished on the basis of greater guideline-recommended statin eligibility and higher rates of statin therapy. Results: Of 47,108 study participants, mean age was 60 years, and 11,020 (23.4%) had CAD. The CAD PRS strongly associated with prevalent CAD (OR=1.4 per SD increase in PRS; p<0.0001). High polygenic risk (top 20% of PRS) conferred 1.9-fold odds of developing CAD (p<0.0001). However, among primary prevention patients (N=33,251), high polygenic risk did not correspond with increased recommendations for statin therapy - per the American College of Cardiology/American Heart Association (46.2% for those with high PRS versus 46.8% for all others, p=0.54) or U.S. Preventive Services Task Force (43.7% versus 43.7%, p=0.99) - or higher rates of statin prescriptions (25.0% versus 23.8%, p=0.04). An additional 4.1% of primary prevention patients may be recommended for statin therapy if high CAD PRS were considered a guideline-based, “risk-enhancing factor.” Conclusions: Current paradigms for primary cardiovascular prevention incompletely capture a polygenic susceptibility to CAD. An opportunity may exist to improve CAD prevention efforts by integrating both genetic and clinical risk.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2020.04.027

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

Metadata

Authors
Aragam, K. G., Dobbyn, A., Judy, R., Chaffin, M., Chaudhary, K., Hindy, G., Cagan, A., Finneran, P., Weng, L.-C., Loos, R. J. F., Nadkarni, G., Cho, J. H., Kember, R. L., Baras, A., Reid, J., Overton, J., Philippakis, A., Ellinor, P. T., Weiss, S. T., Rader, D. J., Lubitz, S. A., Smoller, J. W., Karlson, E. W., Khera, A. V., Kathiresan, S., Do, R., Damrauer, S. M., & Natarajan, P.
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2020-06
Volume
75
Issue
22
Pages
2769-2780
ISSN
0735-1097 (ISSN-L)
OpenAlex
W3028713471
Cited by
138
References
21
FWCI
18.07
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.